Flunitrazolam
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Flunitrazolam is a synthetic depressant of the triazolobenzodiazepine class. It is the triazole structural analog of flunitrazepam (Rohypnol), with approximately ten-fold greater potency.[1] Flunitrazolam is a positive allosteric modulator at GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, zolpidem, zopiclone +2 morebenzodiazepines, zolpidem, zopiclone, alcohol, barbiturates show less
First identified by an analytical laboratory in Germany in October 2016, flunitrazolam has no pharmaceutical history and was never developed for clinical use.[4] It entered online research chemical markets as tablets, blotters, and powder, and was soon detected in clinical poisoning cases across Europe — often alongside synthetic opioids.[5][6] Several jurisdictions have since scheduled the compound, including the UK as Class C,[7] though it remains unscheduled by the US DEA.
Subjective effects include sedation, anterograde amnesia, anxiolysis, muscle relaxation, and disinhibition. The experience is defined by an unusually deep amnesia that can outstrip the perceived level of sedation — users may remain mobile and conversational while forming no memories, a dissociation between function and recall that makes the compound particularly unpredictable. Delusions of sobriety and compulsive redosing are characteristic unsought effects.[2]
Flunitrazolam carries high abuse liability,[3] and no lethal dose, therapeutic index, or controlled toxicity data have been established.safety citation needed Respiratory depression is the primary acute lethal risk, amplified dramatically by co-ingestion of opioids or alcohol — a pattern documented in clinical poisoning cases.[5] The published evidence rests on a single self-administration pharmacokinetic study,[8] in vitro metabolism work, and forensic case series — no clinical trials or binding affinity data exist.
History[edit]
Discovery
Flunitrazolam was first identified in October 2016, when a German analytical laboratory reported it to the EMCDDA Early Warning System.[4][9] No prior description existed in scientific or patent literature, and no synthesizer has been identified — the compound emerged entirely from clandestine production. Its design followed a well-established structural logic: fusing a triazole ring onto flunitrazepam, mirroring the relationship between alprazolam and diazepam, or between clonazolam and clonazepam.[2][10]
Market appearance and detection
Flunitrazolam entered online research chemical markets shortly after identification, sold as pink tablets (typically labeled 0.25 mg), blotters, pellets, and loose powder. By 2016–2017, the Swedish STRIDA project — a national system for monitoring new psychoactive substance poisonings — detected it in clinical intoxication cases, including five of eleven acrylfentanyl poisoning presentations.[5][6] By 2020, flunitrazolam accounted for 58 seizure incidents across the European Union, ranking fourth among tracked designer benzodiazepines.[11] In the United States, novel benzodiazepines including flunitrazolam were identified in whole blood specimens at the New York City Medical Examiner's office.[12]
Regulatory response
The combination of sub-milligram dosing, extreme potency, and documented clinical harms triggered scheduling across multiple jurisdictions. The UK Advisory Council on the Misuse of Drugs assessed flunitrazolam among 11 designer benzodiazepines and explicitly referenced the potential for drug-facilitated sexual assault in its scheduling rationale, placing the compound under Class C of the Misuse of Drugs Act 1971 effective August 2021.[7] Germany controls it under its NpSG blanket legislation, Canada lists it under Schedule IV, and Belgium added it to Annex IVB in 2023.[4][13]
The name flunitrazolam is a systematic compound: flu (fluorine substituent), nitra (nitro group), zolam (triazolobenzodiazepine class suffix). The -zolam ending places it in the same naming lineage as Alprazolam, triazolam, and Clonazolam. Its parent compound Flunitrazepam — marketed as Rohypnol — carries one of the most recognized reputations in drug culture as a date-rape drug. Flunitrazolam inherits and intensifies that association: the UK ACMD's scheduling rationale explicitly cited drug-facilitated sexual assault potential as a factor.[7]
Chemistry[edit]
Structural class
Flunitrazolam belongs to the triazolobenzodiazepine subclass — benzodiazepines with a fused 1,2,4-triazole ring. This triazole fusion is the structural feature shared with alprazolam, triazolam, and clonazolam, and it consistently increases potency relative to the parent compound.[2][10]
Flunitrazolam is the direct triazole structural analog of flunitrazepam (Rohypnol). It retains flunitrazepam's two key substituents — a fluorine-bearing phenyl ring and a nitro group — while adding the triazole ring that defines the -zolam class. The fluorine increases the compound's ability to cross cell membranes; the nitro group influences both receptor binding and how the body metabolizes the drug.[14]
Molecular properties
| Molecular formula | C₁₇H₁₂FN₅O₂ |
| Molecular weight | 337.31 g/mol |
The core structure is a fused three-ring system: a benzene ring, a seven-membered diazepine ring, and the 1,2,4-triazole ring. A fluorine-bearing phenyl group projects from the diazepine ring. The molecule contains five nitrogen atoms distributed across the triazole and diazepine rings.
Stereochemistry
Flunitrazolam lacks a stereocenter in its standard form. Unlike some benzodiazepines where a hydroxyl group at the C3 position creates chirality, flunitrazolam's C3 is part of the fused triazole ring and does not produce separable mirror-image forms.[14]
Physical properties
Flunitrazolam presents as a yellow crystalline powder.[15] It dissolves readily in organic solvents but is expected to have low water solubility based on its lipophilic character. No stability studies under ambient storage conditions have been reported. The nitro group is susceptible to bacterial reduction in unpreserved biological samples — a finding with significant implications for forensic sample handling.[16]
Pharmacology[edit]
Mechanism of action
Flunitrazolam enhances the activity of GABA, the brain's primary inhibitory neurotransmitter. It binds to the benzodiazepine site on GABA-A receptors — a site located between the α and γ₂ subunits of the receptor complex — and increases the frequency with which the receptor's chloride channel opens in response to GABA.[2][3] The compound does not activate the receptor on its own; it amplifies GABA's existing signal.
This amplified inhibitory signaling produces the characteristic benzodiazepine effects: sedation, anxiety reduction, muscle relaxation, seizure suppression, and amnesia. The triazole ring modification that distinguishes flunitrazolam from its parent compound flunitrazepam increases the molecule's lipophilicity and modifies how it interacts with the receptor, producing a more potent effect.[10][2]
The UK Advisory Council on the Misuse of Drugs assessed that flunitrazolam's potency likely exceeds that of flunitrazepam — itself the most potent marketed clinical benzodiazepine.[7] In laboratory tests on rat cortical neurons, flunitrazolam inhibited spontaneous network activity at concentrations as low as 0.01 µM.[1] No specific binding affinity values have been published for flunitrazolam at any GABA-A receptor subtype — a significant gap for a compound of this potency.
Pharmacokinetics
The only controlled human pharmacokinetic data come from a single self-administration study in which a researcher ingested one confirmed 0.25 mg tablet.[8]
Absorption and onset: Flunitrazolam is taken orally in tablets, blotters, or pellets. Effects begin within 20–40 minutes of ingestion. No bioavailability data have been published.
Metabolism: The body processes flunitrazolam through multiple pathways. The primary route is reduction of the nitro group to an amino compound (7-amino-flunitrazolam), confirmed in both liver cell studies and the self-administration study.[14][8] Additional pathways include hydroxylation and glucuronide conjugation. The glucuronidation pathway is pharmacologically unusual: unlike most designer benzodiazepines, which are conjugated by a single enzyme, flunitrazolam appears to require the coordinated action of multiple enzymes for this step.[17] This may contribute to variation in how quickly different individuals eliminate the drug.
Elimination: In the self-administration study, the parent compound was detectable in urine for up to 21 hours, with approximately 3% of the dose excreted unchanged.[8] Metabolites extended the detection window to 37 hours when specifically targeted. The half-life has been estimated at 5–13 hours in secondary sources, but no controlled plasma pharmacokinetic study has confirmed this.safety citation needed
Neuroscience[edit]
Where it acts
Flunitrazolam amplifies inhibitory signaling across distributed brain circuits. In the cortex and thalamus, enhanced GABA activity suppresses arousal-related information flow, producing sedation. In the hippocampus, it disrupts the cellular mechanism of memory formation (long-term potentiation), producing the compound's defining anterograde amnesia. In the amygdala and limbic circuits, it dampens threat reactivity, producing anxiolysis.[3][2] In brainstem respiratory centers, this same amplification of inhibition suppresses breathing drive — the mechanism underlying the potentially lethal respiratory depression.[18] Laboratory studies on cortical neuron networks demonstrated that flunitrazolam suppresses spontaneous activity at concentrations as low as 0.01 µM.[1]
Why it matters
Flunitrazolam's reinforcement potential arises from a specific circuit: it enhances inhibition of interneurons in the ventral tegmental area that normally restrain dopamine release. The result is a surge of dopamine in reward circuits. High-potency, short-acting compounds produce sharper peaks in this dopamine signal, contributing to stronger reinforcement and compulsive redosing.[3] With repeated use, the brain compensates by downregulating GABA-A receptors and sensitizing excitatory glutamate systems — producing tolerance and setting the stage for withdrawal seizures if use stops abruptly.
No neuroimaging or electrophysiology studies have been conducted with flunitrazolam. Whether it preferentially binds to the receptor subtypes responsible for sedation and amnesia (α₁-containing GABA-A receptors), rather than those mediating anxiety relief, is unknown. Whether ultra-potent designer benzodiazepines accelerate the brain's compensatory neuroplastic changes — and thus produce faster tolerance and more severe withdrawal — compared to lower-potency compounds remains an open question. The unusual metabolic profile[17] also raises the possibility that flunitrazolam's duration of action varies more between individuals than is typical for the class.
Subjective Effects[edit]
Flunitrazolam produces a subjective experience dominated by heavy sedation, cognitive suppression, and a pervasive erasure of short-term memory formation. The amnestic effect is disproportionately potent relative to the sedative load: at common doses, users may retain enough motor function to act, speak, and redose while forming no memories of doing so. Set and setting exert less influence than with many psychoactive substances — the pharmacological profile overwhelms contextual factors at common-to-strong doses.
Within the triazolobenzodiazepine class, flunitrazolam's experiential signature most closely resembles triazolam and clonazolam — rapid onset, heavy sedation, pronounced amnesia, steep dose-response — but at substantially lower absolute doses. The compulsive redosing pattern, driven by the convergence of amnesia, delusions of sobriety, and perceived underdosing, is consistently highlighted as a distinctive hazard.[2]
Effect Grid
Clear sedation dominates the experience alongside marked anxiety suppression and muscle relaxation. Anterograde amnesia becomes apparent — memory of events during exposure is patchy and unreliable. Cognitive processing is noticeably slowed, with analysis suppression and information processing suppression clearly present. Emotional suppression flattens affective range.
Physical effects include moderate motor control impairment, bodily heaviness, and mild dizziness. Physical fatigue may encourage lying down. Respiratory depression remains subclinical at this dose in healthy individuals but is dose-dependent.
Disinhibition is present and delusions of sobriety may begin — users may believe they are less impaired than they are. Compulsive redosing risk increases as amnesia impairs recall of prior doses. This is the dose range where the defining risk pattern of flunitrazolam emerges: ambulatory blackout with continued redosing.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Dreaming enhancement
Physical fatigue · Dizziness · Body high · Insomnia · Nystagmus (eye wobbles) · Sexual arousal suppression · Laughter fits · Nausea · Nausea suppression · Restlessness · Seizure threshold reduction · Bodily dissociation
Insomnia · Nystagmus (eye wobbles) · Sexual arousal suppression · Laughter fits · Nausea · Nausea suppression · Restlessness · Bodily dissociation
Cognitive fatigue · Focus suppression · Memory suppression · Thought deceleration · Creativity suppression · Memory fragmentation · Motivation suppression · Thought disorganization · Confusion · Language suppression · Suggestibility enhancement · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Thought deceleration · Creativity suppression · Memory fragmentation · Motivation suppression · Thought disorganization · Confusion · Language suppression · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Empathy suppression · Dysphoria · Emotional lability · Irritability · Anxiety · Anhedonia
Anxiety · Anhedonia
Emotional susceptibility · Sociability suppression · Trust enhancement · Communication enhancement · Sociability enhancement · Depersonalization · Derealization
Sociability enhancement · Depersonalization · Derealization
Timeline
Absorption period with no perceptible effects initially. A faint awareness that something has shifted may emerge toward the end of this phase.
Anxiolysis and mild relaxation become noticeable. Subtle sedation and muscle loosening emerge as GABA-A potentiation builds.
Maximum sedation, anterograde amnesia, muscle relaxation, and anxiolysis. Cognitive suppression and disinhibition at their strongest. Delusions of sobriety may prevent self-assessment of impairment.
Gradual reduction in sedation. Cognitive impairment and memory gaps may persist beyond subjective awareness that peak effects have passed. Motor impairment lingers.
Residual sedation, cognitive fog, and possible next-day drowsiness. Memory of the experience may be incomplete or absent.
⚠ Do not drive or operate heavy machinery for at least 12 hours after ingestion — residual cognitive and motor impairment may persist beyond subjective awareness of drug effects.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · zolpidem · zopiclone
Toxicity
Acute toxicity
No lethal dose data exist for flunitrazolam in any species, and no therapeutic index has been calculated.safety citation needed These are fundamental data gaps for a compound already in circulation at active doses.
The primary acute risk is respiratory depression at doses above the intended range, especially in combination with other depressants. The sub-milligram dosing range (0.1–0.5 mg) creates significant overdose risk from weighing errors alone — milligram-scale miscalculations can produce two- to five-fold dose escalation.[2][9] Unregulated tablets and blotters may be misdosed or adulterated.
Clinical intoxication data
Flunitrazolam has appeared in clinical intoxication cases across multiple countries. In Sweden, the STRIDA project detected it as a co-intoxicant in five of eleven acrylfentanyl poisoning cases, with patients presenting decreased consciousness and respiratory depression.[5] Separate STRIDA analyses confirmed its presence in other benzodiazepine-related poisoning presentations.[6]
It has also been detected in routine drug testing and emergency ward admissions in Sweden[19] and in whole blood specimens at the New York City Medical Examiner's office.[12] By 2020, flunitrazolam accounted for 58 seizure incidents across the EU, ranking fourth among tracked designer benzodiazepines.[11]
Fatalities
No published case reports attribute death specifically to flunitrazolam alone. The compound has been identified as a co-intoxicant in polydrug fatality investigations.[5] The absence of standalone fatality reports should not be interpreted as evidence of safety — it likely reflects detection gaps, the compound's recency, and the predominance of polydrug use in the populations where it circulates.
Chronic toxicity
No data address organ-specific chronic toxicity for flunitrazolam. Class-level concerns include liver burden from ongoing metabolism, cognitive impairment with chronic use, and the brain changes underlying tolerance and dependence.[18]
Psychological risks
Anterograde amnesia is the defining psychological risk. Flunitrazolam produces dose-dependent inability to form new memories during exposure that is characteristically profound. The ACMD flagged this property as particularly concerning given its structural relationship to flunitrazepam, the most clinically potent amnestic benzodiazepine.[7]
Delusions of sobriety — the paradoxical conviction of being unimpaired while profoundly intoxicated — are documented across high-potency designer benzodiazepines.[2] This impairs self-monitoring: users may drive, make consequential decisions, or interact socially without awareness of their functional impairment.
Compulsive redosing is driven by the convergence of amnesia (no memory of having dosed), delusions of sobriety (perceived underdosing), and short-to-intermediate duration. This pattern can produce cumulative toxicity across repeated doses within a single session.
Drug-facilitated sexual assault: Designer benzodiazepines with profiles similar to flunitrazolam have been detected in sexual assault cases.[20] The ACMD explicitly referenced this compound's potential for facilitating assault — citing its high potency, rapid incapacitation, profound amnesia, and short detection window.[7]
Tolerance & dependence
No flunitrazolam-specific tolerance or dependence studies have been published. The following is inferred from the well-characterized class pharmacology of benzodiazepines.[3]
Tolerance develops within days of continuous use as the brain downregulates GABA-A subunits and compensates by sensitizing excitatory glutamate systems. Cross-tolerance is complete with all other benzodiazepines, and partial with other GABA-active depressants including alcohol, z-drugs (zolpidem, zopiclone), and barbiturates.
Dependence liability is expected to be high. High-potency, short-to-intermediate-acting benzodiazepines (triazolam, alprazolam) carry higher physical and psychological dependence liability than longer-acting compounds, owing to more pronounced between-dose withdrawal and sharper reinforcement.[3]
Withdrawal: Abrupt discontinuation after physical dependence produces rebound effect anxiety, insomnia, tremor, sweating, perceptual disturbances, and in severe cases seizures and delirium. Withdrawal seizures can be life-threatening. Management requires gradual dose reduction with a long-acting benzodiazepine such as diazepam.[3][21]
Drug interactions
No substance-specific interaction studies have been published. The following is based on class pharmacology and documented co-intoxication patterns.[2]
Opioids (including fentanyl analogues): The most dangerous documented combination. Flunitrazolam appeared alongside acrylfentanyl in five of eleven STRIDA intoxication cases.[5] Both drug classes suppress breathing through different mechanisms, and the combination produces respiratory failure at doses that would be survivable for either drug alone.
Alcohol: Synergistic depression through dual action on GABA-A receptors (benzodiazepine and ethanol sites) combined with ethanol's additional glutamate suppression.[2] This combination is potentially fatal and is the most common dangerous co-exposure pattern for benzodiazepines as a class.
Other GABA-active depressants (other benzodiazepines, z-drugs, barbiturates, GHB/GBL): Additive or synergistic effects produce unpredictable dose escalation. GHB carries particular risk due to its own steep dose-response curve.
CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, grapefruit juice): Based on structural analogy to alprazolam and triazolam, drugs that inhibit CYP3A4 would be expected to increase flunitrazolam levels in the body, potentially substantially. This has not been experimentally confirmed.inferred
Stimulants: Co-administration with stimulants (amphetamines, cocaine) may mask the subjective perception of sedation, enabling dangerous redosing while respiratory depression accumulates undetected.
Contraindications
No flunitrazolam-specific contraindication studies exist. The following are inferred from class pharmacology and the documented intoxication profile.
Concurrent depressant use (absolute): Co-ingestion with opioids, alcohol, barbiturates, GHB, or other benzodiazepines. The synergistic respiratory depression documented in clinical cases[5] can be fatal.
Respiratory conditions (absolute): Individuals with chronic obstructive pulmonary disease, sleep apnea, or other conditions compromising breathing capacity face elevated risk of respiratory failure.
Liver impairment (relative): Flunitrazolam undergoes complex liver metabolism requiring multiple enzymes for glucuronidation.[17] Liver impairment may disproportionately prolong the drug's effects.
Pregnancy (relative): No reproductive toxicity data exist. General benzodiazepine concerns include birth defect risk in the first trimester, neonatal sedation, and neonatal withdrawal.inferred
History of substance use disorder (relative): The high reinforcement potential and compulsive redosing pattern elevate risk in individuals with a history of sedative or polysubstance use disorder.
Myasthenia gravis (relative): Benzodiazepine-induced muscle relaxation may worsen muscle weakness.inferred
Harm Reduction[edit]
Forms & Identification
Flunitrazolam's sub-milligram active dose range means that conventional field-testing approaches face severe limitations. Standard benzodiazepine immunoassay panels may not detect designer benzodiazepines at all — in one study, 70% of immunoassay-positive but confirmation-negative blood samples contained at least one novel benzodiazepine.[12] Reagent testing can confirm the presence of a benzodiazepine-class compound but cannot distinguish flunitrazolam from other designer benzodiazepines or verify dose accuracy.
For loose powder, a milligram-precision scale (0.001 g) is insufficient for safe dosing at the 0.1–0.5 mg range; a microgram-precision analytical balance would be required. Volumetric dosing — dissolving a known quantity in a measured volume of solvent — is the only practical approach to accurate sub-milligram dosing from powder. Pre-dosed forms (tablets, pellets, blotters) carry their own risks: declared doses may not match actual content, and no quality control applies to any available form.
Guidelines
- Test any material with available reagent kits to confirm benzodiazepine-class identity. Be aware that reagent tests cannot verify dose or distinguish between designer benzodiazepines.
- If working from powder, use volumetric dosing. Do not attempt to weigh sub-milligram doses on a standard milligram scale.
- Start at the lowest reported threshold dose. Flunitrazolam's steep dose-response curve means small increases produce large changes in effect.
- Write down the substance name, dose, and time of ingestion before effects begin. Amnesia will prevent recall of this information later.
- Arrange a sober sitter who understands the amnestic and disinhibiting properties of the compound.
- Secure all remaining substance supply, car keys, and anything that could enable harmful decisions during impairment.
- Do not combine with any other depressant — opioids, alcohol, other benzodiazepines, GHB, or sleep medications.
- Do not plan to redose. If the urge arises, consult the written note of when the first dose was taken.
Set & Setting
Flunitrazolam's pharmacological profile significantly limits the protective value of set and setting at common-to-strong doses. The amnesia and delusions of sobriety override the user's ability to self-monitor, making a trusted, sober companion the single most important environmental safeguard.
A sober sitter should be prepared to prevent redosing (the amnestic user will not remember having taken a dose), monitor breathing, and intervene if the user attempts to drive or leave a safe environment. All doses and the time of administration should be written down in a visible location before effects begin.
Aftercare & integration. Flunitrazolam's amnestic properties mean that much or all of the experience under its influence may be unrecoverable. Users frequently report waking with no memory of hours of activity, sometimes discovering evidence of actions they cannot recall. This memory gap can be distressing.
After use, prioritize sleep, hydration, and light nutrition. Residual grogginess and impaired coordination may persist beyond the subjective duration of effects. Do not drive or operate machinery until full alertness has returned.
If disturbing gaps in memory emerge, speak with the sober companion who was present or review any written records. If use has become a pattern rather than an isolated event, the aftercare phase is the appropriate time to honestly assess that trajectory.
Recovery & Support
Benzodiazepine dependence is a serious medical condition that requires supervised management. Abrupt discontinuation of flunitrazolam or any benzodiazepine after physical dependence has developed risks life-threatening withdrawal seizures.[3][21]
Anyone seeking to stop regular benzodiazepine use should consult a physician experienced in benzodiazepine tapering. The standard approach involves gradual dose reduction using a long-acting benzodiazepine such as diazepam. The tapering process may take weeks to months depending on the duration and intensity of use.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), Benzodiazepine Information Coalition (benzoinfo.com), and local addiction medicine services. Peer support communities focused specifically on benzodiazepine withdrawal exist online and can provide practical guidance from people who have navigated the process.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, irregular, or stops
- Lips, fingertips, or skin turn blue or grey
- The person cannot be roused by voice or firm physical stimulation
- Seizures occur, especially in someone who has been using regularly and stopped abruptly
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive.
- Place the person in the recovery position (on their side, airway clear) to prevent choking.
- Monitor breathing continuously. If breathing stops, begin rescue breathing if trained.
- Do not leave the person alone. Do not induce vomiting.
- If opioid co-ingestion is suspected, administer naloxone first — it reverses opioid-driven respiratory depression but will not reverse benzodiazepine effects.
What to tell the dispatcher: Name the substance (flunitrazolam, a designer benzodiazepine), the approximate dose and time of ingestion, any co-ingested substances, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil is a competitive antagonist that can reverse benzodiazepine-induced sedation and respiratory depression.[22] It is administered in hospital settings only. Flumazenil may trigger seizures in benzodiazepine-dependent individuals and wears off faster than most benzodiazepines, requiring repeated doses. In polydrug overdoses involving opioids, naloxone should be administered first or alongside flumazenil.[5]
Legal Status[edit]
Flunitrazolam occupies a patchwork legal status internationally. Several jurisdictions have enacted specific controls since its emergence in 2016, while others rely on structural analog provisions or have not yet addressed it. No jurisdiction has approved flunitrazolam for any medical, veterinary, or research purpose.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class C (Misuse of Drugs Act 1971); Schedule 1 (MDR 2001) | Effective 18 August 2021. Schedule 1 — the most restrictive tier — reflects no known legitimate medicinal use. Home Office licence required for possession[7] |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Covered by blanket NPS legislation[4] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Specific scheduling confirmed[4] |
| Belgium | Annex IVB | Added approximately April 2023[13] |
| United States | Not explicitly DEA-scheduled | Not included in the DEA's temporary scheduling orders that placed five other designer benzodiazepines into Schedule I (2022–2026). The Federal Analogue Act may apply if deemed substantially similar to a scheduled substance and intended for human consumptionsafety citation needed |
| Sweden | Detected in clinical settings (2016–2017) | Scheduling status not confirmed in available research[5] |
| Australia | Status unconfirmed | Not found in TGA database search |
Analogue considerations
In jurisdictions without specific scheduling, flunitrazolam may fall under analogue legislation. In the United States, the Federal Analogue Act extends Schedule I/II controls to substances "substantially similar" in chemical structure or pharmacological effect to a listed controlled substance, when intended for human consumption. Flunitrazolam's structural relationship to flunitrazepam (Schedule IV) and its pharmacological similarity to Schedule I designer benzodiazepines (clonazolam, flualprazolam, flubromazolam) provide potential grounds for prosecution, though the legal interpretation is case-specific and untested for flunitrazolam.citation needed
references
- [1] ^abcWopken JP, Thornton JR, van Kleef RGDM, Westerink RHS (2026) Inhibitory effects of (synthetic) cannabinoids and (designer) benzodiazepines on spontaneously active neuronal networks of primary rat cortical cultures in vitro — Neurotoxicology doi:10.1016/j.neuro.2025.103379
- [2]
- [3]
- [4]
- [5]
- [6] ^abcBäckberg M, Pettersson Bergstrand M, Beck O, Helander A (2019) Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. — Clinical Toxicology doi:10.1080/15563650.2018.1506130